1315 Capital II, L.P.
Transaction: 01/20/2026
SELL
Change
-19,000
Price
$2.02
Filing
02/17/2026
Type
SELL
Interpace Biosciences, Inc.
IDXG • Medical - Diagnostics & Research
$5.30
▲ +0.30 (+6.00%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$146.88M
Growth
-6.8%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 63.5%Positive free cash flow · 1.24Reasonable earnings multiple · 0.22Manageable debt level · 0.05Healthy liquidity · 1.94
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:30 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$5.30
Change6.00%
Shares Out27.71M
Market Cap$146.88M
Enterprise Value$144.71M
52W Range0.77 - 2.40
Beta0.61
P/E6.01
P/S4.06
P/B6.32
P/FCF39.22
EV/Sales4.00
Price$5.30
Change6.00%
Shares Out27.71M
Market Cap$146.88M
Enterprise Value$144.71M
52W Range0.77 - 2.40
Beta0.61
P/E6.01
P/S4.06
P/B6.32
P/FCF39.22
EV/Sales4.00
EV/EBITDA30.94
EV/FCF38.64
Earnings Yield16.64%
FCF Yield2.55%
Dividend Yield0.00%
Gross Margin62.31%
Oper. Margin10.55%
Profit Margin63.46%
Debt/Eq0.05
Current Ratio1.94
Quick Ratio1.94
Revenue 5Y-6.82%
FCF 5Y-3.73%
Volume12.66K
Avg Volume5.50K
EPS Surprise1.46
Investment DNA
How strong this company looks for long-term investors
77
out of 100
Business Quality
Margins, moat, returns
74/100
Financial Strength
Debt, cash, stability
94/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Stable or improving margins · 63.5%Positive free cash flow · 1.24Reasonable earnings multiple · 0.22Manageable debt level · 0.05Healthy liquidity · 1.94
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 7 analyst votes · 2026-10-21
93/100
Bullish
Bullish
6
Hold
1
Bearish
0
Insider Transactions
Recent executive and insider activity
1315 Capital II, L.P.
Transaction: 01/20/2026
BUY
Change
+9,405,941
Price
$2.02
Filing
02/17/2026
Type
BUY
Ampersand 2018 Limited Partnership
Transaction: 01/20/2026
SELL
Change
-28,000
Price
$2.02
Filing
02/04/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| 1315 Capital II, L.P. | SELL | -19,000 | $2.02 | 01/20/2026 | 02/17/2026 |
| 1315 Capital II, L.P. | BUY | +9,405,941 | $2.02 | 01/20/2026 | 02/17/2026 |
| Ampersand 2018 Limited Partnership | SELL | -28,000 | $2.02 | 01/20/2026 | 02/04/2026 |
| Ampersand 2018 Limited Partnership | BUY | +13,861,386 | $2.02 | 01/20/2026 | 02/04/2026 |
| McCarthy Christopher | BUY | +1,111 | Not reported | 12/01/2024 | 04/25/2025 |
| McCarthy Christopher | BUY | +15,112 | Not reported | 07/27/2024 | 04/25/2025 |
| McCarthy Christopher | BUY | +6,045 | Not reported | 02/01/2024 | 04/25/2025 |
| McCarthy Christopher | BUY | +7,556 | Not reported | 01/31/2024 | 04/25/2025 |
| McCarthy Christopher | BUY | +1,095 | Not reported | 12/01/2023 | 04/25/2025 |
| McCarthy Christopher | BUY | +7,556 | Not reported | 07/31/2023 | 04/25/2025 |
| Ampersand 2018 Limited Partnership | BUY | +28,000 | $6.00 | 10/11/2024 | 10/15/2024 |
| Ampersand 2018 Limited Partnership | BUY | +28,000 | $2.02 | 10/11/2024 | 10/15/2024 |
| 1315 Capital II, L.P. | BUY | +19,000 | $6.00 | 10/11/2024 | 10/15/2024 |
| 1315 Capital II, L.P. | BUY | +19,000 | $2.02 | 10/11/2024 | 10/15/2024 |
| McCarthy Christopher | BUY | +10,000 | Not reported | 02/01/2024 | 02/06/2024 |
| McCarthy Christopher | BUY | +25,000 | Not reported | 07/31/2023 | 08/01/2023 |
| McCarthy Christopher | SELL | -2,500 | $6.00 | 04/21/2023 | 05/03/2023 |
| McCarthy Christopher | SELL | -5,000 | Not reported | 04/21/2023 | 05/03/2023 |
| McCarthy Christopher | SELL | 0 | Not reported | 04/21/2023 | 05/03/2023 |
| AGGARWAL VIJAY | OTHER | 0 | Not reported | 02/01/2022 | 02/02/2022 |